TEFLARO® CABP Study in pediatrics: Selected patient demographics and baseline characteristics (MITT)4 | ||
Patient Demographics |
TEFLARO
(n=121) |
Ceftriaxone
(n=39) |
Age, median years (range) | 4.0 (0.2-17.0) | 3.0 (0.4-16.0) |
Age cohort (range) | ||
12 years - <18 years n (%) | 8 (6.6) | 2 (5.1) |
6 years - <12 years n (%) | 26 (21.5) | 9 (23.1) |
2 years - <6 years n (%) | 64 (52.9) | 21 (53.8) |
2 months - <2 years n (%) | 23 (19.0) | 7 (17.9) |
Male sex (%) | 64 (52.9) | 20 (51.3) |
BMI (kg/m2) mean (SD) | 16.3 (3.3) | 15.8 (3.0) |
Creatinine clearance,
mL/min/1.73 m2 |
||
Mean (SD) | 105.1 (30.6) | 103.7 (39.4) |
≥50 mL/min/1.72 m2 n (%) | 120 (99.2)* | 39 (100.0) |
Disease characteristics | ||
History of pneumococcal vaccination n (%) | 54 (50.5) | 18 (50.0) |
C-reactive protein (mg/dL) Mean (SD) | 11.1 (12.9) | 12.4 (12.5) |
Radiographic assessment | ||
Chest x-ray completed n (%) | 107 (100.0) | 36 (100.0) |
Pleural effusion present n (%) | ||
Unilateral | 12 (11.2) | 10 (27.8) |
Bilateral | 0 | 1 (2.8) |
Lobes involved in pulmonary infiltrate n (%) | ||
One lobe | 75 (70.1) | 22 (61.1) |
Multiple lobes | 32 (29.9) |
14 (38.9)
|
TEFLARO® CABP study in pediatrics: Selected patient demographics and baseline characteristics (MITT)4 | |
Patient Demographics | |
TEFLARO
(n=121) |
Ceftriaxone
(n=39) |
Age, median years (range) | |
4.0 (0.2-17.0) | 3.0 (0.4-16.0) |
Age cohort (range) | |
12 years - <18 years n (%) | |
8 (6.6) | 2 (5.1) |
6 years - <12 years n (%) | |
26 (21.5) | 9 (23.1) |
2 years - <6 years n (%) | |
64 (52.9) | 21 (53.8) |
2 months - <2 years n (%) | |
23 (19.0) | 7 (17.9) |
Male sex (%) | |
64 (52.9) | 20 (51.3) |
BMI (kg/m2) mean (SD) | |
16.3 (3.3) | 15.8 (3.0) |
Creatinine clearance, mL/min/1.73 m2 | |
Mean (SD) | |
105.1 (30.6) | 103.7 (39.4) |
≥50 mL/min/1.72 m2 n (%) | |
120 (99.2)* | 39 (100.0) |
Disease characteristics | |
History of pneumococcal vaccination n (%) | |
54 (50.5) | 18 (50.0) |
C-reactive protein (mg/dL) Mean (SD) |
|
11.1 (12.9) | 12.4 (12.5) |
Radiographic assessment | |
Chest x-ray completed n (%) | |
107 (100.0) | 36 (100.0) |
Pleural effusion present n (%) | |
Unilateral | |
12 (11.2) | 10 (27.8) |
Bilateral | |
0 | 1 (2.8) |
Lobes involved in pulmonary infiltrate n (%) | |
One lobe | |
75 (70.1) | 22 (61.1) |
Multiple lobes | |
32 (29.9) | 14 (38.9) |
* | Data missing for one patient. |
Data on file. Allergan, Inc. | |
BMI=body mass index; SD=standard deviation. |
Learn about TEFLARO dosing in pediatric patients based on age and weight
SEE DOSINGPlease also see full Prescribing Information.
Please also see full Prescribing Information.